Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Mesothelioma | 37 | 2024 | 806 | 5.210 |
Why?
|
Pleural Neoplasms | 28 | 2024 | 609 | 3.610 |
Why?
|
Lung Neoplasms | 87 | 2024 | 13249 | 2.530 |
Why?
|
Peritoneal Neoplasms | 7 | 2020 | 706 | 1.560 |
Why?
|
Ubiquitin Thiolesterase | 9 | 2024 | 454 | 1.410 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 38 | 2024 | 5248 | 1.310 |
Why?
|
Adenocarcinoma | 24 | 2017 | 6310 | 1.010 |
Why?
|
Tumor Suppressor Proteins | 10 | 2024 | 2804 | 0.940 |
Why?
|
Immunohistochemistry | 25 | 2024 | 11064 | 0.910 |
Why?
|
Solitary Fibrous Tumor, Pleural | 2 | 2019 | 25 | 0.840 |
Why?
|
Peritoneum | 3 | 2023 | 225 | 0.820 |
Why?
|
Gene Amplification | 7 | 2012 | 1085 | 0.690 |
Why?
|
Molecular Targeted Therapy | 6 | 2024 | 2805 | 0.480 |
Why?
|
Mutation | 30 | 2024 | 29950 | 0.480 |
Why?
|
Gene Dosage | 8 | 2012 | 1218 | 0.470 |
Why?
|
Tissue Array Analysis | 4 | 2013 | 551 | 0.430 |
Why?
|
Biopsy | 5 | 2020 | 6775 | 0.420 |
Why?
|
Translocation, Genetic | 2 | 2018 | 1388 | 0.420 |
Why?
|
In Situ Hybridization, Fluorescence | 11 | 2018 | 2500 | 0.410 |
Why?
|
Asbestos | 1 | 2013 | 251 | 0.400 |
Why?
|
Adenocarcinoma, Bronchiolo-Alveolar | 6 | 2009 | 88 | 0.380 |
Why?
|
Carcinogens | 1 | 2013 | 449 | 0.380 |
Why?
|
Esophageal Neoplasms | 5 | 2009 | 1651 | 0.340 |
Why?
|
Genes, erbB-1 | 2 | 2007 | 160 | 0.340 |
Why?
|
Neurofibromin 2 | 2 | 2020 | 270 | 0.310 |
Why?
|
Oncogene Proteins, Fusion | 5 | 2018 | 1591 | 0.300 |
Why?
|
Protein-Tyrosine Kinases | 5 | 2014 | 2415 | 0.290 |
Why?
|
Neoplasm Staging | 22 | 2024 | 11141 | 0.290 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p16 | 4 | 2019 | 698 | 0.280 |
Why?
|
Proto-Oncogene Proteins c-kit | 2 | 2009 | 729 | 0.270 |
Why?
|
Carcinoma, Squamous Cell | 7 | 2020 | 4024 | 0.270 |
Why?
|
Humans | 132 | 2024 | 760261 | 0.270 |
Why?
|
Pneumonectomy | 8 | 2019 | 1110 | 0.270 |
Why?
|
Aged, 80 and over | 28 | 2024 | 58947 | 0.270 |
Why?
|
Hemangioendothelioma, Epithelioid | 1 | 2006 | 53 | 0.260 |
Why?
|
Lymphoma, Non-Hodgkin | 1 | 2013 | 1378 | 0.260 |
Why?
|
Prognosis | 29 | 2021 | 29636 | 0.260 |
Why?
|
Hodgkin Disease | 1 | 2013 | 1381 | 0.260 |
Why?
|
Aged | 47 | 2024 | 168995 | 0.250 |
Why?
|
SOXB1 Transcription Factors | 3 | 2012 | 286 | 0.250 |
Why?
|
Ribs | 1 | 2006 | 254 | 0.250 |
Why?
|
Neoplasms, Mesothelial | 1 | 2024 | 3 | 0.240 |
Why?
|
Adenocarcinoma, Mucinous | 2 | 2007 | 517 | 0.240 |
Why?
|
Carcinoma, Signet Ring Cell | 1 | 2005 | 83 | 0.240 |
Why?
|
CpG Islands | 2 | 2008 | 1221 | 0.230 |
Why?
|
Diagnosis, Differential | 13 | 2024 | 12968 | 0.230 |
Why?
|
Pleura | 3 | 2024 | 243 | 0.230 |
Why?
|
Receptor Protein-Tyrosine Kinases | 5 | 2018 | 1614 | 0.230 |
Why?
|
Lipoma | 1 | 2006 | 292 | 0.230 |
Why?
|
Middle Aged | 49 | 2024 | 220175 | 0.220 |
Why?
|
Kaplan-Meier Estimate | 8 | 2018 | 6545 | 0.220 |
Why?
|
Antineoplastic Agents, Phytogenic | 4 | 2012 | 625 | 0.220 |
Why?
|
Antineoplastic Agents | 16 | 2023 | 13629 | 0.220 |
Why?
|
In Situ Hybridization | 1 | 2007 | 1900 | 0.220 |
Why?
|
Nuclear Proteins | 5 | 2023 | 5793 | 0.220 |
Why?
|
Microsatellite Repeats | 1 | 2005 | 786 | 0.210 |
Why?
|
Male | 62 | 2024 | 359413 | 0.210 |
Why?
|
Lymphatic Metastasis | 6 | 2017 | 2945 | 0.210 |
Why?
|
Female | 64 | 2024 | 391011 | 0.200 |
Why?
|
Adult | 37 | 2024 | 219847 | 0.200 |
Why?
|
Thoracic Surgical Procedures | 2 | 2020 | 347 | 0.200 |
Why?
|
Spectroscopy, Near-Infrared | 3 | 2017 | 740 | 0.190 |
Why?
|
DNA Mutational Analysis | 6 | 2020 | 4109 | 0.190 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 7 | 2013 | 1729 | 0.190 |
Why?
|
Practice Guidelines as Topic | 6 | 2019 | 7468 | 0.180 |
Why?
|
Gastrointestinal Stromal Tumors | 1 | 2006 | 615 | 0.180 |
Why?
|
Piperazines | 2 | 2012 | 2520 | 0.180 |
Why?
|
Tumor Necrosis Factor Receptor-Associated Peptides and Proteins | 1 | 2019 | 44 | 0.170 |
Why?
|
Survival Rate | 13 | 2016 | 12806 | 0.170 |
Why?
|
Antibodies, Monoclonal | 6 | 2018 | 9196 | 0.170 |
Why?
|
Thymus Neoplasms | 2 | 2013 | 274 | 0.160 |
Why?
|
Paclitaxel | 3 | 2012 | 1738 | 0.160 |
Why?
|
Shoulder Joint | 1 | 2006 | 730 | 0.160 |
Why?
|
Gene Deletion | 2 | 2019 | 2668 | 0.160 |
Why?
|
Gene Expression Regulation, Neoplastic | 11 | 2014 | 8498 | 0.160 |
Why?
|
Histone-Lysine N-Methyltransferase | 2 | 2020 | 679 | 0.160 |
Why?
|
Pyrimidines | 2 | 2009 | 3011 | 0.150 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p18 | 1 | 2017 | 52 | 0.150 |
Why?
|
Transcription Factors | 4 | 2023 | 12100 | 0.150 |
Why?
|
Horses | 1 | 2018 | 299 | 0.150 |
Why?
|
Pyridinium Compounds | 1 | 2017 | 81 | 0.150 |
Why?
|
Immunoenzyme Techniques | 5 | 2013 | 1705 | 0.140 |
Why?
|
Smoking | 3 | 2011 | 9070 | 0.140 |
Why?
|
Predictive Value of Tests | 9 | 2024 | 15273 | 0.140 |
Why?
|
Carcinoma | 2 | 2005 | 2334 | 0.140 |
Why?
|
Protein Kinase Inhibitors | 9 | 2017 | 5640 | 0.140 |
Why?
|
Genes, ras | 6 | 2009 | 654 | 0.140 |
Why?
|
Observer Variation | 4 | 2017 | 2596 | 0.140 |
Why?
|
Medical Oncology | 5 | 2023 | 2321 | 0.140 |
Why?
|
High-Throughput Nucleotide Sequencing | 2 | 2020 | 3618 | 0.140 |
Why?
|
Neoplasm Metastasis | 8 | 2017 | 4891 | 0.130 |
Why?
|
Neurofibromatosis 2 | 1 | 2020 | 385 | 0.130 |
Why?
|
Mitotic Index | 2 | 2020 | 161 | 0.130 |
Why?
|
Cyclin-Dependent Kinases | 2 | 2017 | 656 | 0.130 |
Why?
|
DNA Methylation | 3 | 2012 | 4374 | 0.130 |
Why?
|
Polymers | 3 | 2012 | 1620 | 0.120 |
Why?
|
Quinazolines | 4 | 2009 | 1363 | 0.120 |
Why?
|
Neoplasm Recurrence, Local | 6 | 2022 | 9274 | 0.120 |
Why?
|
Bone Neoplasms | 1 | 2006 | 2532 | 0.120 |
Why?
|
Thymoma | 2 | 2013 | 187 | 0.120 |
Why?
|
Young Adult | 11 | 2020 | 58673 | 0.120 |
Why?
|
Sarcoma | 2 | 2017 | 1786 | 0.120 |
Why?
|
Drug Resistance, Neoplasm | 6 | 2018 | 5230 | 0.110 |
Why?
|
Adolescent | 11 | 2020 | 87747 | 0.110 |
Why?
|
World Health Organization | 2 | 2021 | 1319 | 0.110 |
Why?
|
Immunotherapy | 5 | 2022 | 4637 | 0.110 |
Why?
|
Receptor, trkB | 1 | 2014 | 125 | 0.110 |
Why?
|
Neoplasms | 5 | 2017 | 22066 | 0.110 |
Why?
|
Brain Neoplasms | 3 | 2010 | 8984 | 0.110 |
Why?
|
ras Proteins | 4 | 2013 | 1051 | 0.110 |
Why?
|
Esophagectomy | 3 | 2007 | 469 | 0.110 |
Why?
|
Multiple Pulmonary Nodules | 1 | 2015 | 167 | 0.100 |
Why?
|
Gene Rearrangement | 3 | 2013 | 1122 | 0.100 |
Why?
|
Research Report | 1 | 2016 | 370 | 0.100 |
Why?
|
Taxoids | 2 | 2016 | 668 | 0.100 |
Why?
|
Combined Modality Therapy | 7 | 2017 | 8551 | 0.100 |
Why?
|
Thoracic Surgery, Video-Assisted | 1 | 2015 | 277 | 0.100 |
Why?
|
Diffusion Magnetic Resonance Imaging | 1 | 2024 | 2776 | 0.100 |
Why?
|
Disease-Free Survival | 4 | 2020 | 6830 | 0.100 |
Why?
|
Pathology, Clinical | 1 | 2016 | 375 | 0.100 |
Why?
|
Radiotherapy, Adjuvant | 3 | 2011 | 1790 | 0.100 |
Why?
|
Cell Nucleus | 4 | 2020 | 2909 | 0.100 |
Why?
|
Depsipeptides | 1 | 2012 | 95 | 0.100 |
Why?
|
Solitary Pulmonary Nodule | 1 | 2015 | 270 | 0.100 |
Why?
|
Collagen | 2 | 2010 | 2635 | 0.100 |
Why?
|
Tomography, X-Ray Computed | 3 | 2015 | 20484 | 0.100 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 5 | 2018 | 11708 | 0.100 |
Why?
|
Cisplatin | 2 | 2009 | 1642 | 0.100 |
Why?
|
Sensitivity and Specificity | 7 | 2024 | 14656 | 0.090 |
Why?
|
Lymph Nodes | 2 | 2013 | 3491 | 0.090 |
Why?
|
Lung | 5 | 2020 | 9989 | 0.090 |
Why?
|
Paired Box Transcription Factors | 1 | 2011 | 207 | 0.090 |
Why?
|
Therapies, Investigational | 1 | 2011 | 111 | 0.090 |
Why?
|
Early Detection of Cancer | 2 | 2018 | 3215 | 0.090 |
Why?
|
Receptor, Notch1 | 1 | 2013 | 495 | 0.090 |
Why?
|
Western World | 1 | 2009 | 26 | 0.090 |
Why?
|
Mitogen-Activated Protein Kinase Kinases | 2 | 2012 | 642 | 0.090 |
Why?
|
Carcinoma, Lewis Lung | 1 | 2010 | 107 | 0.080 |
Why?
|
Cell Line, Tumor | 12 | 2016 | 16905 | 0.080 |
Why?
|
Gene Expression Regulation, Enzymologic | 1 | 2014 | 1173 | 0.080 |
Why?
|
Pathology, Surgical | 1 | 2011 | 151 | 0.080 |
Why?
|
Drug Delivery Systems | 2 | 2012 | 2218 | 0.080 |
Why?
|
Clinical Trials, Phase II as Topic | 1 | 2012 | 629 | 0.080 |
Why?
|
Amifostine | 1 | 2009 | 40 | 0.080 |
Why?
|
Biopsy, Fine-Needle | 1 | 2014 | 1111 | 0.080 |
Why?
|
Lymphoma, Mantle-Cell | 1 | 2012 | 237 | 0.080 |
Why?
|
Colorectal Neoplasms | 2 | 2008 | 6855 | 0.080 |
Why?
|
Chemotherapy, Adjuvant | 3 | 2011 | 3531 | 0.080 |
Why?
|
Chondrosarcoma | 1 | 2011 | 296 | 0.080 |
Why?
|
Sentinel Lymph Node Biopsy | 1 | 2013 | 727 | 0.080 |
Why?
|
Proportional Hazards Models | 4 | 2017 | 12532 | 0.080 |
Why?
|
Radiation-Protective Agents | 1 | 2009 | 88 | 0.080 |
Why?
|
Cytogenetic Analysis | 1 | 2009 | 271 | 0.080 |
Why?
|
Chromosomes, Human, Pair 4 | 1 | 2009 | 377 | 0.080 |
Why?
|
Carcinoma, Adenosquamous | 1 | 2009 | 66 | 0.080 |
Why?
|
Neoplasm Proteins | 2 | 2013 | 3613 | 0.080 |
Why?
|
Neoadjuvant Therapy | 5 | 2023 | 2811 | 0.080 |
Why?
|
Endopeptidases | 1 | 2012 | 772 | 0.080 |
Why?
|
Cytoprotection | 1 | 2009 | 200 | 0.080 |
Why?
|
Disease Models, Animal | 7 | 2012 | 18134 | 0.080 |
Why?
|
Staining and Labeling | 1 | 2012 | 1090 | 0.080 |
Why?
|
Animals | 24 | 2018 | 167940 | 0.080 |
Why?
|
Phenotype | 3 | 2019 | 16543 | 0.080 |
Why?
|
Polyesters | 1 | 2010 | 372 | 0.080 |
Why?
|
Chromogenic Compounds | 1 | 2007 | 31 | 0.070 |
Why?
|
Receptor, erbB-2 | 2 | 2009 | 2544 | 0.070 |
Why?
|
Professional Role | 1 | 2011 | 311 | 0.070 |
Why?
|
Endocytosis | 1 | 2012 | 960 | 0.070 |
Why?
|
Pharmacogenetics | 1 | 2012 | 680 | 0.070 |
Why?
|
Genes, APC | 1 | 2008 | 145 | 0.070 |
Why?
|
Receptor, Platelet-Derived Growth Factor alpha | 1 | 2009 | 367 | 0.070 |
Why?
|
Genome, Human | 3 | 2010 | 4416 | 0.070 |
Why?
|
DNA Modification Methylases | 1 | 2008 | 208 | 0.070 |
Why?
|
Oncogenes | 2 | 2011 | 1221 | 0.070 |
Why?
|
Discriminant Analysis | 1 | 2007 | 223 | 0.070 |
Why?
|
Surgery, Computer-Assisted | 1 | 2015 | 1007 | 0.070 |
Why?
|
Histone Deacetylase Inhibitors | 1 | 2012 | 772 | 0.070 |
Why?
|
MAP Kinase Kinase 2 | 1 | 2007 | 92 | 0.070 |
Why?
|
Tonsillar Neoplasms | 1 | 2007 | 50 | 0.070 |
Why?
|
Disease Progression | 5 | 2018 | 13505 | 0.070 |
Why?
|
Germ-Line Mutation | 2 | 2020 | 1843 | 0.070 |
Why?
|
Bronchial Neoplasms | 1 | 2007 | 110 | 0.070 |
Why?
|
Frozen Sections | 1 | 2007 | 153 | 0.070 |
Why?
|
Radiotherapy | 1 | 2013 | 1505 | 0.070 |
Why?
|
Benzimidazoles | 1 | 2012 | 858 | 0.070 |
Why?
|
Neoplasm Invasiveness | 3 | 2012 | 3618 | 0.070 |
Why?
|
Camptothecin | 1 | 2010 | 590 | 0.070 |
Why?
|
Tissue Fixation | 1 | 2007 | 241 | 0.070 |
Why?
|
DNA Repair Enzymes | 1 | 2008 | 345 | 0.070 |
Why?
|
Reproducibility of Results | 8 | 2024 | 20048 | 0.070 |
Why?
|
Proto-Oncogene Proteins c-met | 1 | 2010 | 567 | 0.070 |
Why?
|
Hyperthermia, Induced | 2 | 2009 | 415 | 0.070 |
Why?
|
Genetic Techniques | 1 | 2009 | 428 | 0.070 |
Why?
|
Proto-Oncogene Proteins | 4 | 2013 | 4494 | 0.070 |
Why?
|
Tumor Cells, Cultured | 5 | 2013 | 6131 | 0.060 |
Why?
|
MAP Kinase Kinase 1 | 1 | 2007 | 332 | 0.060 |
Why?
|
HSP90 Heat-Shock Proteins | 1 | 2008 | 423 | 0.060 |
Why?
|
Carboplatin | 1 | 2008 | 789 | 0.060 |
Why?
|
Cytodiagnosis | 2 | 2021 | 432 | 0.060 |
Why?
|
Thiazolidinediones | 1 | 2008 | 465 | 0.060 |
Why?
|
Microscopy, Electron | 1 | 2009 | 2558 | 0.060 |
Why?
|
Drug Carriers | 1 | 2010 | 706 | 0.060 |
Why?
|
Analysis of Variance | 1 | 2013 | 6242 | 0.060 |
Why?
|
Sequence Deletion | 3 | 2020 | 1493 | 0.060 |
Why?
|
Proto-Oncogene Proteins c-mdm2 | 1 | 2007 | 368 | 0.060 |
Why?
|
Mice | 19 | 2013 | 81216 | 0.060 |
Why?
|
Esophagogastric Junction | 1 | 2007 | 341 | 0.060 |
Why?
|
Sirolimus | 2 | 2009 | 1548 | 0.060 |
Why?
|
Genetics, Population | 1 | 2009 | 929 | 0.060 |
Why?
|
Cell Differentiation | 4 | 2010 | 11480 | 0.060 |
Why?
|
Age Factors | 3 | 2017 | 18415 | 0.060 |
Why?
|
DNA-Binding Proteins | 2 | 2020 | 9590 | 0.060 |
Why?
|
Precancerous Conditions | 1 | 2011 | 978 | 0.060 |
Why?
|
Carcinoma, Papillary | 1 | 2009 | 785 | 0.060 |
Why?
|
Benzamides | 2 | 2007 | 1369 | 0.060 |
Why?
|
Indocyanine Green | 2 | 2017 | 236 | 0.060 |
Why?
|
Imidazoles | 1 | 2009 | 1178 | 0.050 |
Why?
|
Enzyme Inhibitors | 3 | 2010 | 3726 | 0.050 |
Why?
|
Membrane Glycoproteins | 1 | 2014 | 3731 | 0.050 |
Why?
|
Nanoparticles | 2 | 2012 | 1938 | 0.050 |
Why?
|
Epigenesis, Genetic | 2 | 2008 | 3758 | 0.050 |
Why?
|
Blotting, Western | 4 | 2013 | 5039 | 0.050 |
Why?
|
Immunosuppressive Agents | 1 | 2016 | 4168 | 0.050 |
Why?
|
Tumor Burden | 2 | 2019 | 1897 | 0.050 |
Why?
|
Treatment Outcome | 10 | 2017 | 64947 | 0.050 |
Why?
|
Genes, p53 | 3 | 2012 | 714 | 0.050 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2013 | 2927 | 0.050 |
Why?
|
Pyrroles | 1 | 2009 | 1137 | 0.050 |
Why?
|
Mitogen-Activated Protein Kinases | 1 | 2007 | 1246 | 0.050 |
Why?
|
Cell Movement | 1 | 2014 | 5206 | 0.050 |
Why?
|
Survival Analysis | 3 | 2010 | 10185 | 0.050 |
Why?
|
AMP-Activated Protein Kinases | 3 | 2012 | 600 | 0.050 |
Why?
|
Demography | 1 | 2006 | 1650 | 0.050 |
Why?
|
Consensus | 2 | 2024 | 3106 | 0.050 |
Why?
|
Serous Membrane | 1 | 2021 | 25 | 0.050 |
Why?
|
Cell Survival | 5 | 2010 | 5796 | 0.050 |
Why?
|
Cooperative Behavior | 1 | 2009 | 1500 | 0.050 |
Why?
|
Evidence-Based Medicine | 3 | 2019 | 3696 | 0.050 |
Why?
|
Cytomegalovirus Infections | 1 | 2008 | 831 | 0.050 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 4 | 2010 | 4573 | 0.050 |
Why?
|
Mice, Transgenic | 6 | 2008 | 9531 | 0.050 |
Why?
|
Drug Evaluation, Preclinical | 3 | 2012 | 1346 | 0.050 |
Why?
|
Indoles | 1 | 2009 | 1830 | 0.050 |
Why?
|
Polymorphism, Single Nucleotide | 5 | 2016 | 15766 | 0.050 |
Why?
|
Proto-Oncogene Proteins B-raf | 2 | 2008 | 2052 | 0.050 |
Why?
|
Genes, Tumor Suppressor | 3 | 2011 | 1056 | 0.050 |
Why?
|
Intraoperative Care | 2 | 2015 | 768 | 0.040 |
Why?
|
Patient Selection | 2 | 2011 | 4276 | 0.040 |
Why?
|
Pyridines | 1 | 2012 | 2877 | 0.040 |
Why?
|
Preoperative Care | 2 | 2007 | 2255 | 0.040 |
Why?
|
Lymph Node Excision | 2 | 2017 | 1305 | 0.040 |
Why?
|
Genetic Predisposition to Disease | 2 | 2019 | 17766 | 0.040 |
Why?
|
Phosphatidylinositol 3-Kinases | 1 | 2008 | 2866 | 0.040 |
Why?
|
Sequence Analysis, DNA | 1 | 2010 | 4717 | 0.040 |
Why?
|
Apolipoproteins B | 1 | 2000 | 388 | 0.040 |
Why?
|
Diagnostic Imaging | 1 | 2013 | 3526 | 0.040 |
Why?
|
Protein Methyltransferases | 1 | 2018 | 54 | 0.040 |
Why?
|
Angiogenesis Inhibitors | 1 | 2009 | 2047 | 0.040 |
Why?
|
Mice, Nude | 3 | 2011 | 3605 | 0.040 |
Why?
|
Guidelines as Topic | 2 | 2016 | 1395 | 0.040 |
Why?
|
Genetic Markers | 1 | 2005 | 2608 | 0.040 |
Why?
|
Case-Control Studies | 3 | 2015 | 22041 | 0.040 |
Why?
|
MAP Kinase Signaling System | 3 | 2012 | 1483 | 0.040 |
Why?
|
Indolizines | 1 | 2017 | 30 | 0.040 |
Why?
|
Head and Neck Neoplasms | 1 | 2012 | 2880 | 0.040 |
Why?
|
Mice, Mutant Strains | 2 | 2014 | 1760 | 0.040 |
Why?
|
Sex Factors | 4 | 2015 | 10530 | 0.040 |
Why?
|
Molecular Diagnostic Techniques | 2 | 2013 | 612 | 0.040 |
Why?
|
International Cooperation | 2 | 2016 | 1436 | 0.040 |
Why?
|
Cyclic N-Oxides | 1 | 2017 | 73 | 0.040 |
Why?
|
Fluorescent Dyes | 2 | 2017 | 1914 | 0.040 |
Why?
|
Cell Proliferation | 4 | 2021 | 10434 | 0.040 |
Why?
|
Follow-Up Studies | 4 | 2017 | 39254 | 0.040 |
Why?
|
Patient Care Team | 1 | 2009 | 2510 | 0.040 |
Why?
|
Enzyme Activation | 3 | 2010 | 3604 | 0.040 |
Why?
|
NIH 3T3 Cells | 2 | 2009 | 670 | 0.040 |
Why?
|
Phosphorylation | 4 | 2009 | 8314 | 0.040 |
Why?
|
Cell Cycle | 1 | 2005 | 2937 | 0.040 |
Why?
|
Area Under Curve | 1 | 2021 | 1635 | 0.040 |
Why?
|
Recurrence | 3 | 2017 | 8487 | 0.040 |
Why?
|
Genes, Neoplasm | 2 | 2010 | 370 | 0.040 |
Why?
|
Polymorphism, Genetic | 1 | 2007 | 4286 | 0.030 |
Why?
|
Australasia | 1 | 2016 | 21 | 0.030 |
Why?
|
Ribonucleoprotein, U2 Small Nuclear | 1 | 2016 | 21 | 0.030 |
Why?
|
Feasibility Studies | 3 | 2013 | 5201 | 0.030 |
Why?
|
Clinical Trials, Phase I as Topic | 1 | 2017 | 326 | 0.030 |
Why?
|
Multivariate Analysis | 2 | 2006 | 12156 | 0.030 |
Why?
|
Apoptosis | 3 | 2008 | 9497 | 0.030 |
Why?
|
Early Diagnosis | 1 | 2021 | 1181 | 0.030 |
Why?
|
Drug Administration Schedule | 2 | 2017 | 4900 | 0.030 |
Why?
|
Lipoproteins | 1 | 2000 | 882 | 0.030 |
Why?
|
Hypoglycemic Agents | 1 | 2008 | 3149 | 0.030 |
Why?
|
Epithelial-Mesenchymal Transition | 1 | 2020 | 730 | 0.030 |
Why?
|
Homozygote | 1 | 2020 | 1786 | 0.030 |
Why?
|
Fatal Outcome | 1 | 2020 | 1833 | 0.030 |
Why?
|
Societies, Medical | 2 | 2018 | 3903 | 0.030 |
Why?
|
Maximum Tolerated Dose | 2 | 2009 | 877 | 0.030 |
Why?
|
Postoperative Complications | 2 | 2015 | 15680 | 0.030 |
Why?
|
Risk Factors | 5 | 2013 | 74269 | 0.030 |
Why?
|
DNA, Neoplasm | 2 | 2010 | 1745 | 0.030 |
Why?
|
Point Mutation | 2 | 2010 | 1594 | 0.030 |
Why?
|
Colonic Neoplasms | 1 | 2005 | 2526 | 0.030 |
Why?
|
Hypoxia-Inducible Factor 1 | 1 | 2014 | 193 | 0.030 |
Why?
|
Gene Expression Profiling | 4 | 2013 | 9388 | 0.030 |
Why?
|
Public Opinion | 1 | 2017 | 481 | 0.030 |
Why?
|
Tissue Distribution | 1 | 2017 | 2262 | 0.030 |
Why?
|
ROC Curve | 1 | 2021 | 3568 | 0.030 |
Why?
|
Down-Regulation | 2 | 2012 | 2918 | 0.030 |
Why?
|
Kidney Transplantation | 1 | 2008 | 4215 | 0.030 |
Why?
|
Triglycerides | 1 | 2000 | 2476 | 0.030 |
Why?
|
Oligonucleotide Array Sequence Analysis | 2 | 2013 | 3774 | 0.030 |
Why?
|
Glioblastoma | 1 | 2007 | 3482 | 0.020 |
Why?
|
Injections, Intradermal | 1 | 2012 | 116 | 0.020 |
Why?
|
Cell Cycle Proteins | 1 | 2023 | 3448 | 0.020 |
Why?
|
Xenograft Model Antitumor Assays | 2 | 2011 | 3584 | 0.020 |
Why?
|
Quinolines | 2 | 2007 | 759 | 0.020 |
Why?
|
Protein Isoforms | 1 | 2016 | 1697 | 0.020 |
Why?
|
Genetic Testing | 2 | 2015 | 3530 | 0.020 |
Why?
|
Alternative Splicing | 1 | 2016 | 1091 | 0.020 |
Why?
|
Fluorescence | 1 | 2013 | 750 | 0.020 |
Why?
|
Canada | 1 | 2016 | 2128 | 0.020 |
Why?
|
Protein Stability | 1 | 2012 | 566 | 0.020 |
Why?
|
Interferon-gamma | 1 | 2018 | 3160 | 0.020 |
Why?
|
RNA Interference | 2 | 2009 | 2846 | 0.020 |
Why?
|
Chromosomes, Human, Pair 21 | 1 | 2010 | 228 | 0.020 |
Why?
|
RNA, Messenger | 2 | 2020 | 12762 | 0.020 |
Why?
|
Gene Knockdown Techniques | 1 | 2014 | 1617 | 0.020 |
Why?
|
Acetylation | 1 | 2012 | 1062 | 0.020 |
Why?
|
Paraffin Embedding | 1 | 2010 | 302 | 0.020 |
Why?
|
Genotype | 3 | 2009 | 12959 | 0.020 |
Why?
|
History, 21st Century | 1 | 2015 | 1576 | 0.020 |
Why?
|
INDEL Mutation | 1 | 2010 | 266 | 0.020 |
Why?
|
Europe | 1 | 2016 | 3433 | 0.020 |
Why?
|
Cyclin-Dependent Kinase 6 | 1 | 2012 | 346 | 0.020 |
Why?
|
Drug Compounding | 1 | 2010 | 245 | 0.020 |
Why?
|
Biomarkers, Pharmacological | 1 | 2009 | 162 | 0.020 |
Why?
|
Uteroglobin | 1 | 2008 | 56 | 0.020 |
Why?
|
Glucose | 1 | 2000 | 4361 | 0.020 |
Why?
|
Randomized Controlled Trials as Topic | 2 | 2018 | 10340 | 0.020 |
Why?
|
Chromosomes, Human, Pair 3 | 1 | 2009 | 313 | 0.020 |
Why?
|
Karyotyping | 1 | 2010 | 1172 | 0.020 |
Why?
|
Cyclin-Dependent Kinase 4 | 1 | 2012 | 556 | 0.020 |
Why?
|
Intracellular Signaling Peptides and Proteins | 2 | 2009 | 2874 | 0.020 |
Why?
|
Microscopy, Electron, Scanning | 1 | 2010 | 941 | 0.020 |
Why?
|
Radiography, Interventional | 1 | 2015 | 1112 | 0.020 |
Why?
|
Intraoperative Period | 1 | 2009 | 516 | 0.020 |
Why?
|
Proto-Oncogenes | 1 | 2008 | 320 | 0.020 |
Why?
|
Norway | 1 | 2009 | 497 | 0.020 |
Why?
|
Substrate Specificity | 1 | 2012 | 1792 | 0.020 |
Why?
|
Chromosomes, Human, Pair 5 | 1 | 2009 | 385 | 0.020 |
Why?
|
Models, Chemical | 1 | 2009 | 614 | 0.020 |
Why?
|
Activin Receptors, Type I | 1 | 2008 | 136 | 0.020 |
Why?
|
Ubiquitination | 1 | 2012 | 1010 | 0.020 |
Why?
|
Antigens, Nuclear | 1 | 2008 | 184 | 0.020 |
Why?
|
Adaptor Proteins, Signal Transducing | 2 | 2008 | 2895 | 0.020 |
Why?
|
Chromosomes, Human, Pair 8 | 1 | 2009 | 452 | 0.020 |
Why?
|
Oral Ulcer | 1 | 2008 | 96 | 0.020 |
Why?
|
Clinical Laboratory Techniques | 1 | 2012 | 749 | 0.020 |
Why?
|
Chromosomes, Human, Pair 14 | 1 | 2007 | 286 | 0.020 |
Why?
|
Genes, p16 | 1 | 2007 | 159 | 0.020 |
Why?
|
Protein Tyrosine Phosphatases | 1 | 2009 | 459 | 0.020 |
Why?
|
Phosphoproteins | 1 | 2016 | 2441 | 0.020 |
Why?
|
Time Factors | 3 | 2017 | 40133 | 0.020 |
Why?
|
Surface Properties | 1 | 2010 | 1158 | 0.020 |
Why?
|
Retrospective Studies | 5 | 2017 | 80301 | 0.020 |
Why?
|
RNA Editing | 1 | 2008 | 151 | 0.020 |
Why?
|
Reference Standards | 1 | 2010 | 1004 | 0.020 |
Why?
|
Signal Transduction | 4 | 2014 | 23363 | 0.020 |
Why?
|
Prospective Studies | 3 | 2020 | 54263 | 0.020 |
Why?
|
Disease Management | 1 | 2017 | 2508 | 0.020 |
Why?
|
In Situ Nick-End Labeling | 1 | 2007 | 613 | 0.020 |
Why?
|
Delayed-Action Preparations | 1 | 2010 | 961 | 0.020 |
Why?
|
Biological Assay | 1 | 2009 | 630 | 0.020 |
Why?
|
Epidemiologic Methods | 1 | 2011 | 1344 | 0.020 |
Why?
|
HeLa Cells | 1 | 2012 | 3105 | 0.020 |
Why?
|
Cluster Analysis | 1 | 2013 | 2698 | 0.020 |
Why?
|
Insulin | 1 | 2000 | 6592 | 0.020 |
Why?
|
Tyrphostins | 1 | 2005 | 63 | 0.020 |
Why?
|
Health Planning Guidelines | 1 | 2006 | 151 | 0.020 |
Why?
|
Cyclin D2 | 1 | 2005 | 98 | 0.020 |
Why?
|
PPAR gamma | 1 | 2008 | 484 | 0.020 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2014 | 2449 | 0.020 |
Why?
|
Janus Kinase 3 | 1 | 2005 | 77 | 0.020 |
Why?
|
HT29 Cells | 1 | 2005 | 190 | 0.020 |
Why?
|
Loss of Heterozygosity | 1 | 2007 | 659 | 0.020 |
Why?
|
Doxycycline | 1 | 2007 | 337 | 0.020 |
Why?
|
RNA, Neoplasm | 1 | 2008 | 749 | 0.020 |
Why?
|
Mice, Knockout | 2 | 2013 | 14396 | 0.020 |
Why?
|
Liver | 1 | 2000 | 7512 | 0.020 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2005 | 358 | 0.010 |
Why?
|
Microscopy, Fluorescence | 1 | 2012 | 2651 | 0.010 |
Why?
|
Cadherins | 1 | 2009 | 898 | 0.010 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 1 | 2008 | 896 | 0.010 |
Why?
|
Image Processing, Computer-Assisted | 1 | 2021 | 8945 | 0.010 |
Why?
|
Pathology, Molecular | 1 | 2007 | 330 | 0.010 |
Why?
|
Neoplasms, Hormone-Dependent | 1 | 2007 | 412 | 0.010 |
Why?
|
Wnt Proteins | 1 | 2008 | 718 | 0.010 |
Why?
|
Hospitals, Community | 1 | 2006 | 367 | 0.010 |
Why?
|
Chromosome Aberrations | 1 | 2010 | 1767 | 0.010 |
Why?
|
Fluorodeoxyglucose F18 | 1 | 2012 | 2007 | 0.010 |
Why?
|
Cyclins | 1 | 2005 | 593 | 0.010 |
Why?
|
Tissue Scaffolds | 1 | 2010 | 927 | 0.010 |
Why?
|
Genetic Engineering | 1 | 2009 | 933 | 0.010 |
Why?
|
Chromosome Deletion | 1 | 2007 | 1387 | 0.010 |
Why?
|
Rabbits | 1 | 2009 | 4773 | 0.010 |
Why?
|
Apoptosis Regulatory Proteins | 1 | 2008 | 1135 | 0.010 |
Why?
|
Algorithms | 2 | 2013 | 13967 | 0.010 |
Why?
|
Gene Frequency | 1 | 2009 | 3605 | 0.010 |
Why?
|
Mitosis | 1 | 2007 | 1193 | 0.010 |
Why?
|
Chromosome Mapping | 1 | 2010 | 4625 | 0.010 |
Why?
|
Swine | 1 | 2012 | 5902 | 0.010 |
Why?
|
Neoplasm, Residual | 1 | 2007 | 1008 | 0.010 |
Why?
|
Administration, Oral | 1 | 2009 | 4044 | 0.010 |
Why?
|
Gene Silencing | 1 | 2008 | 1511 | 0.010 |
Why?
|
Protein Kinases | 1 | 2008 | 1612 | 0.010 |
Why?
|
Pilot Projects | 1 | 2014 | 8553 | 0.010 |
Why?
|
Clinical Trials as Topic | 1 | 2017 | 8058 | 0.010 |
Why?
|
Transplantation, Heterologous | 1 | 2009 | 2378 | 0.010 |
Why?
|
Oleic Acid | 1 | 2000 | 92 | 0.010 |
Why?
|
Cell Lineage | 1 | 2009 | 2525 | 0.010 |
Why?
|
Boston | 1 | 2013 | 9282 | 0.010 |
Why?
|
Glucose Clamp Technique | 1 | 2000 | 263 | 0.010 |
Why?
|
Exons | 1 | 2006 | 2391 | 0.010 |
Why?
|
RNA-Binding Proteins | 1 | 2009 | 1892 | 0.010 |
Why?
|
Treatment Failure | 1 | 2006 | 2646 | 0.010 |
Why?
|
Models, Molecular | 1 | 2009 | 5429 | 0.010 |
Why?
|
Palliative Care | 1 | 2014 | 3607 | 0.010 |
Why?
|
TOR Serine-Threonine Kinases | 1 | 2008 | 2058 | 0.010 |
Why?
|
Protein Structure, Tertiary | 1 | 2006 | 3800 | 0.010 |
Why?
|
United States | 2 | 2018 | 72363 | 0.010 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 1 | 2005 | 1408 | 0.010 |
Why?
|
Neovascularization, Pathologic | 1 | 2009 | 2641 | 0.010 |
Why?
|
Glucagon | 1 | 2000 | 532 | 0.010 |
Why?
|
Wound Healing | 1 | 2009 | 2786 | 0.010 |
Why?
|
Flow Cytometry | 1 | 2009 | 5873 | 0.010 |
Why?
|
Drug Therapy, Combination | 1 | 2008 | 6499 | 0.010 |
Why?
|
Risk Assessment | 2 | 2010 | 24086 | 0.010 |
Why?
|
RNA | 1 | 2007 | 2721 | 0.010 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2009 | 10829 | 0.010 |
Why?
|
Immunoglobulin G | 1 | 2009 | 4546 | 0.010 |
Why?
|
Image Interpretation, Computer-Assisted | 1 | 2010 | 3335 | 0.010 |
Why?
|
Promoter Regions, Genetic | 1 | 2008 | 5784 | 0.010 |
Why?
|
Cohort Studies | 2 | 2009 | 41317 | 0.010 |
Why?
|
Massachusetts | 1 | 2009 | 8805 | 0.010 |
Why?
|
Positron-Emission Tomography | 1 | 2012 | 6457 | 0.010 |
Why?
|
Fasting | 1 | 2000 | 1603 | 0.010 |
Why?
|
Models, Biological | 1 | 2010 | 9468 | 0.010 |
Why?
|
Dexamethasone | 1 | 2000 | 1928 | 0.010 |
Why?
|
Kinetics | 1 | 2000 | 6378 | 0.010 |
Why?
|
Genomics | 1 | 2007 | 5790 | 0.010 |
Why?
|
Mice, Inbred C57BL | 1 | 2009 | 22025 | 0.010 |
Why?
|
Child | 1 | 2019 | 79758 | 0.010 |
Why?
|
Glucocorticoids | 1 | 2000 | 2143 | 0.010 |
Why?
|
Membrane Proteins | 1 | 2008 | 7854 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 2 | 2008 | 36247 | 0.010 |
Why?
|
Genome-Wide Association Study | 1 | 2009 | 12602 | 0.010 |
Why?
|
Rats, Sprague-Dawley | 1 | 2000 | 8157 | 0.010 |
Why?
|
Incidence | 1 | 2005 | 21378 | 0.000 |
Why?
|
Blood Glucose | 1 | 2000 | 6375 | 0.000 |
Why?
|
Cells, Cultured | 1 | 2000 | 18968 | 0.000 |
Why?
|
Rats | 1 | 2000 | 23695 | 0.000 |
Why?
|